Our Pipeline

Our Portfolio of PIKA Technology
Product Candidates

Yisheng has three therapeutic candidates in clinical stages of development. In addition, Yisheng has multiple preclinical programs, including candidates targeting influenza, herpes zoster, Ebola, and other indications.

Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Development Plan
YSJA
Rabies Vaccine
Post-exposure
prophylaxis
Marketed
PIKA
Rabies Vaccine
Post-exposure
prophylaxis
Global Phase 3 initiation
(2020)
YS-HBV-001 Hepatitis B
prevention
China Phase 2 initiation
(2H19)
YS-ON-001 Advanced
solid tumors
China Phase 1 initiation
(2H19)
YS-ON-002 Advanced
solid tumors
 U.S. IND submission
(2020)
YS-HBV-002 Chronic
hepatitis B
treatment
Global
Phase 1 initiation
(2020)